This trial is active, not recruiting.

Condition prostate cancer
Sponsor Oregon Health and Science University
Start date September 2009
End date September 2010
Trial size 5 participants
Trial identifier NCT00980993, OHSU IRB00005606


Patient anatomy and position during the course of radiation therapy can vary from those used for treatment planning; a function of patient movement, uncertainty in positioning system, and organ motion. Traditionally, treatment margins are designed to compensate for interfraction prostate setup variability. This approach has the potential to lower the overall effectiveness of treatment because the prostate gland is a continuously moving target whose motion cannot be accurately accounted for solely on the basis of interfraction movement. More recently, the dosimetric relevance of intra-fraction prostate motion has been recognized, and may be compensated for by continuous real-time adaptive radiation therapy afforded by the Calypso 4D Localization System™. In the current study, the investigators propose to characterize intrafraction prostate motion. The investigators hypothesize that intrafraction prostate motion is correlated with respiratory motion.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Histologically confirmed stage I-III adenocarcinoma of the prostate gland - Age > 18 years. Males of all races and ethnic groups - Scheduled to receive radiation for definitive therapy - Three (3) electromagnetic transponders implanted into prostate gland Exclusion Criteria: - Does not satisfy inclusion criteria

Additional Information

Official title Pilot Study on the Quantification of Respiratory-induced Prostate Motion During Radiation Therapy Using Continuous Real-time Tracking
Principal investigator James A. Tanyi, Ph.D.
Trial information was received from ClinicalTrials.gov and was last updated in September 2009.
Information provided to ClinicalTrials.gov by Oregon Health and Science University.